(EW) Edwards Lifesciences - Overview
Stock: Valves, Replacement, Surgical, Repair, Tissue
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 26.3% |
| Relative Tail Risk | -14.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.42 |
| Alpha | 1.32 |
| Character TTM | |
|---|---|
| Beta | 0.526 |
| Beta Downside | 0.516 |
| Drawdowns 3y | |
|---|---|
| Max DD | 37.53% |
| CAGR/Max DD | 0.02 |
Description: EW Edwards Lifesciences January 29, 2026
Edwards Lifesciences (NYSE:EW) develops and sells minimally invasive cardiovascular devices, including the SAPIEN transcatheter aortic valve replacement (TAVR) system, the PASCAL and Cardioband platforms for mitral and tricuspid repair, and the surgical RESILIA valve family (INSPIRIS, KONECT, MITRIS). The firm operates globally through a direct sales force and independent distributors, and it has been publicly traded since its spin-off from Baxter in 2011.
In its most recent fiscal year (2023), Edwards reported revenue of $5.1 billion, a 12% year-over-year increase driven primarily by a 20% rise in TAVR sales and a 9% lift in surgical valve volumes. The U.S. TAVR market is projected to grow at a CAGR of ~9% through 2028, supported by an aging population (≈ 20% of adults ≥ 65 in the U.S.) and expanding reimbursement pathways for percutaneous valve therapies.
Key economic sensitivities include the company’s exposure to Medicare-DRG pricing reforms and the pace of adoption for newer transcatheter technologies in Europe and Japan, where regulatory timelines can delay revenue realization. Assuming current pricing trends hold, Edwards’ operating margin of ≈ 30% suggests a robust cost structure, but a material shift in reimbursement could compress profitability.
For a deeper, data-driven look at how these dynamics translate into valuation metrics, consider exploring ValueRay’s analytical platform.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 1.36b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 5.21 > 1.0 |
| NWC/Revenue: 81.09% < 20% (prev 89.64%; Δ -8.55% < -1%) |
| CFO/TA 0.11 > 3% & CFO 1.42b > Net Income 1.36b |
| Net Debt (-1.99b) to EBITDA (1.74b): -1.14 < 3 |
| Current Ratio: 4.00 > 1.5 & < 3 |
| Outstanding Shares: last quarter (585.7m) vs 12m ago -2.07% < -2% |
| Gross Margin: 78.22% > 18% (prev 0.79%; Δ 7742 % > 0.5%) |
| Asset Turnover: 44.84% > 50% (prev 41.14%; Δ 3.70% > 0%) |
| Interest Coverage Ratio: 80.08 > 6 (EBITDA TTM 1.74b / Interest Expense TTM 19.8m) |
Altman Z'' 10.00
| A: 0.36 (Total Current Assets 6.36b - Total Current Liabilities 1.59b) / Total Assets 13.27b |
| B: 1.07 (Retained Earnings 14.15b / Total Assets 13.27b) |
| C: 0.12 (EBIT TTM 1.59b / Avg Total Assets 13.12b) |
| D: 4.75 (Book Value of Equity 14.56b / Total Liabilities 3.07b) |
| Altman-Z'' Score: 11.63 = AAA |
Beneish M -2.88
| DSRI: 1.00 (Receivables 892.8m/811.5m, Revenue 5.88b/5.34b) |
| GMI: 1.01 (GM 78.22% / 79.37%) |
| AQI: 1.11 (AQ_t 0.38 / AQ_t-1 0.34) |
| SGI: 1.10 (Revenue 5.88b / 5.34b) |
| TATA: -0.00 (NI 1.36b - CFO 1.42b) / TA 13.27b) |
| Beneish M-Score: -2.88 (Cap -4..+1) = A |
What is the price of EW shares?
Over the past week, the price has changed by -1.79%, over one month by -2.46%, over three months by -1.17% and over the past year by +15.02%.
Is EW a buy, sell or hold?
- StrongBuy: 10
- Buy: 4
- Hold: 17
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the EW price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 97 | 21.6% |
| Analysts Target Price | 97 | 21.6% |
| ValueRay Target Price | 83.8 | 5% |
EW Fundamental Data Overview February 03, 2026
P/E Forward = 28.6533
P/S = 8.247
P/B = 4.6265
P/EG = 4.5837
Revenue TTM = 5.88b USD
EBIT TTM = 1.59b USD
EBITDA TTM = 1.74b USD
Long Term Debt = 598.2m USD (from longTermDebt, last quarter)
Short Term Debt = 26.8m USD (from shortTermDebt, last quarter)
Debt = 700.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.99b USD (from netDebt column, last quarter)
Enterprise Value = 46.54b USD (48.52b + Debt 700.3m - CCE 2.69b)
Interest Coverage Ratio = 80.08 (Ebit TTM 1.59b / Interest Expense TTM 19.8m)
EV/FCF = 38.59x (Enterprise Value 46.54b / FCF TTM 1.21b)
FCF Yield = 2.59% (FCF TTM 1.21b / Enterprise Value 46.54b)
FCF Margin = 20.50% (FCF TTM 1.21b / Revenue TTM 5.88b)
Net Margin = 23.19% (Net Income TTM 1.36b / Revenue TTM 5.88b)
Gross Margin = 78.22% ((Revenue TTM 5.88b - Cost of Revenue TTM 1.28b) / Revenue TTM)
Gross Margin QoQ = 77.77% (prev 77.64%)
Tobins Q-Ratio = 3.51 (Enterprise Value 46.54b / Total Assets 13.27b)
Interest Expense / Debt = 2.83% (Interest Expense 19.8m / Debt 700.3m)
Taxrate = 16.10% (56.1m / 348.4m)
NOPAT = 1.33b (EBIT 1.59b * (1 - 16.10%))
Current Ratio = 4.00 (Total Current Assets 6.36b / Total Current Liabilities 1.59b)
Debt / Equity = 0.07 (Debt 700.3m / totalStockholderEquity, last quarter 10.21b)
Debt / EBITDA = -1.14 (Net Debt -1.99b / EBITDA 1.74b)
Debt / FCF = -1.65 (Net Debt -1.99b / FCF TTM 1.21b)
Total Stockholder Equity = 10.22b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.40% (Net Income 1.36b / Total Assets 13.27b)
RoE = 13.35% (Net Income TTM 1.36b / Total Stockholder Equity 10.22b)
RoCE = 14.66% (EBIT 1.59b / Capital Employed (Equity 10.22b + L.T.Debt 598.2m))
RoIC = 12.30% (NOPAT 1.33b / Invested Capital 10.82b)
WACC = 7.77% (E(48.52b)/V(49.22b) * Re(7.85%) + D(700.3m)/V(49.22b) * Rd(2.83%) * (1-Tc(0.16)))
Discount Rate = 7.85% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.76%
[DCF Debug] Terminal Value 74.54% ; FCFF base≈924.4m ; Y1≈709.7m ; Y5≈442.9m
Fair Price DCF = 18.30 (EV 8.63b - Net Debt -1.99b = Equity 10.62b / Shares 580.3m; r=7.77% [WACC]; 5y FCF grow -27.59% → 2.90% )
EPS Correlation: -33.82 | EPS CAGR: -46.41% | SUE: -4.0 | # QB: 0
Revenue Correlation: 53.39 | Revenue CAGR: 4.23% | SUE: 0.31 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.69 | Chg30d=+0.012 | Revisions Net=+7 | Analysts=22
EPS next Year (2026-12-31): EPS=2.91 | Chg30d=+0.041 | Revisions Net=+11 | Growth EPS=+12.6% | Growth Revenue=+9.7%